DNA (DS) Antibody Test

If you have lupus, suspect you might, or carry risk factors for autoimmune disease, this test answers a question no standard lab panel can: is your immune system making antibodies that attack your own DNA? A positive result, especially at high levels, is one of the strongest signals pointing toward systemic lupus erythematosus (SLE), and tracking changes in your number over time can reveal flares before symptoms fully surface.

Anti-dsDNA (anti-double-stranded DNA) antibodies are not part of a routine blood panel. A normal complete blood count, metabolic panel, or even a basic ANA (antinuclear antibody) screen does not tell you whether these antibodies are present. They require a separate, specific test, and when positive, they carry more diagnostic weight for lupus than almost any other single autoantibody.

What This Test Measures

This test measures antibody proteins (mostly the IgG type, the kind most associated with disease) that your B cells, a type of white blood cell that produces antibodies, make against your body's own double-stranded DNA. In a healthy immune system, B cells learn to ignore the body's own molecules. When that tolerance breaks down, some B cells start making antibodies against normal DNA. These antibodies then form clumps called immune complexes that deposit in tissues, especially the kidneys, triggering inflammation and damage.

The level of anti-dsDNA in your blood reflects how active this self-attacking immune process is. Rising levels often mean the autoimmune engine is revving up, while falling levels after treatment suggest the process is quieting down. This makes anti-dsDNA one of the rare autoantibodies where serial tracking is genuinely useful, not just a one-time diagnostic check.

Lupus Diagnosis

Anti-dsDNA antibodies are a formal classification criterion for SLE. Their specificity for lupus is very high, meaning false alarms are rare: if this test is positive (especially at high levels), lupus is by far the most likely explanation. A systematic review of multiple studies found the Crithidia luciliae immunofluorescence method (a microscopy-based test considered the gold standard for specificity) had a pooled specificity of about 98.7% for SLE. However, the test misses a substantial number of people who do have lupus. Its sensitivity is moderate, around 35% to 70% depending on the assay used. That means a negative result does not rule out lupus.

A large prospective study of 441 people without lupus who had detectable anti-dsDNA found that roughly 85% of them went on to develop SLE within a few years. This finding reinforces that a positive result, even in someone who does not yet have a lupus diagnosis, should be taken seriously and followed closely.

Lupus Nephritis and Kidney Risk

The strongest and most clinically actionable association for this test is with lupus nephritis, the form of kidney inflammation driven by lupus. IgG antibodies to double-stranded DNA are tightly linked to the severity of kidney damage seen on biopsy. In one study of 40 patients with lupus nephritis, IgG anti-dsDNA levels correlated with the degree of active inflammation in kidney tissue, making them a useful non-invasive window into what is happening inside the kidneys.

A prospective study of 48 children and adolescents with lupus but no kidney disease at diagnosis tracked average anti-dsDNA levels over time. For every 100 IU/mL increase in average anti-dsDNA, the risk of developing biopsy-proven lupus nephritis rose by about 29%. Those in the highest third of average anti-dsDNA levels had roughly 17 times the risk of developing kidney disease compared to those in the lowest third. These associations held up after adjusting for other factors like complement levels (a set of blood proteins that drop when the immune system is actively consuming them) and markers of inflammation.

In established lupus nephritis, the combination of positive anti-dsDNA and positive anti-C1q antibodies (another immune marker) predicted worse kidney survival, with about a four-fold higher risk of poor renal outcome compared to patients without both markers.

Cardiovascular Risk in Lupus

Beyond the kidneys, persistently positive anti-dsDNA signals elevated cardiovascular risk in lupus patients. A study of 80 SLE patients found that those with persistent anti-dsDNA positivity had worse blood vessel function, more inflammation-promoting immune activity, and thicker walls in the carotid arteries (major blood vessels in the neck), a sign of early plaque buildup, compared to lupus patients without these antibodies. This means your anti-dsDNA status may help gauge not just lupus activity but also your long-term heart and vascular health.

Positive Results Outside of Lupus

Anti-dsDNA antibodies can appear in conditions other than lupus, though usually at lower levels and with different clinical significance.

• Autoimmune hepatitis: About 40% to 60% of people with ANA-positive type 1 autoimmune hepatitis (a condition where the immune system attacks the liver) have detectable anti-dsDNA. In this setting, the antibodies signal general immune activation rather than classic lupus, and their presence was linked to a poorer initial response to steroid treatment in one study of 53 patients.
• Rheumatoid arthritis on TNF-blocker therapy: Patients treated with infliximab, a medication that blocks a specific inflammatory signal called TNF, commonly develop new anti-dsDNA antibodies, with rates reaching 57% in one study. These are usually low-level, often IgM type (a kind generally considered less concerning than IgG) rather than IgG, and rarely cause lupus-like symptoms. In long-term follow-up, the anti-dsDNA rise was transient and returned to baseline by about 78 weeks.
• Other autoimmune and inflammatory conditions: Low levels can occasionally be found in other autoimmune diseases and infections. A positive result always needs to be interpreted alongside your symptoms, physical exam, and other lab results.

Assay Differences Matter

Not all anti-dsDNA tests are the same. Different lab methods detect different subsets of these antibodies, and results from one method are not directly interchangeable with another. This is one of the most common sources of confusion for both patients and clinicians.

High-avidity anti-dsDNA (the strongly binding type, best detected by the Farr assay) is more tightly linked to severe flares, kidney disease, and brain involvement than low-avidity antibodies detected only by less selective methods. A study of 540 SLE patients found that the EliA assay was more specific during quiet disease, while both EliA and Farr performed similarly during active flares.

The practical takeaway: always compare your results using the same lab and the same test method. Switching between assays can make your numbers look like they have changed when the underlying biology has not.

Reference Ranges

Anti-dsDNA results are typically reported as positive or negative with a numeric value in IU/mL (international units per milliliter). There is no single universal cutpoint. Each lab sets its own threshold based on the assay it uses, and manufacturer-recommended cutoffs do not always match what population data show.

The largest study to establish population-based reference intervals tested 2,880 healthy Chinese Han adults across three common ELISA platforms (AESKU, EUROIMMUNE, INOVA). It found that manufacturer cutoffs were often much higher than the actual 97.5th percentile in healthy people. Upper reference limits varied by age and sex: women tended to have slightly higher levels than men during middle age, and adults over 71 had higher upper limits than younger groups. This means a borderline result could be normal for an older woman but unusual for a young man.

Because assay-specific cutoffs vary widely, the numeric value matters less than the trend over time using the same lab and method.

When Results Can Be Misleading

Several situations can make a single anti-dsDNA result hard to interpret.

• TNF-blocker therapy: Medications like infliximab that block a specific inflammatory signal (TNF), used for rheumatoid arthritis or inflammatory bowel disease, can trigger new anti-dsDNA antibodies in up to half of patients. These are usually transient, mostly the IgM type rather than the disease-associated IgG type, and do not mean you have lupus. If you are on a TNF-blocker and your anti-dsDNA turns positive, your doctor should evaluate for lupus symptoms before changing treatment.
• Assay switching: Different test methods can give very different numbers for the same blood sample. A "rising" level that was measured on two different platforms may be a testing artifact, not a true biological change.
• Acute infections and inflammation: Non-specific immune activation during severe infections can transiently raise autoantibody levels without indicating autoimmune disease.
• Corticosteroid dose: In SLE patients, higher prednisone doses correlate with higher anti-dsDNA. This likely reflects that sicker patients get more steroids, not that steroids cause the antibodies to rise.

Tracking Your Trend

Anti-dsDNA is one of the few autoantibodies where serial measurement genuinely changes clinical decisions. Most autoantibodies are tested once for diagnosis and then left alone. Anti-dsDNA is different because its levels rise and fall with lupus activity, and catching a rising trend early can trigger treatment adjustments that prevent a full flare.

In one study, pre-emptive changes in therapy when anti-dsDNA rose by more than 50% reduced the rate of subsequent flares. This means the value of this test is not in any single number but in seeing where your number is heading. A result of 80 IU/mL that was 30 IU/mL three months ago tells a very different story than a stable 80 IU/mL over two years.

For tracking to be meaningful, use the same lab and the same assay method every time. A reasonable cadence for someone with active lupus is every 3 to 6 months, or more frequently during flares or medication changes. If your disease is in stable remission, testing every 6 to 12 months keeps the trend visible without over-testing.